Comparison 1. Somatostatin analogues versus none.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Perioperative mortality	18	2210	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.56, 1.16]
2 Treatment withdrawal	9	1220	Risk Ratio (M‐H, Fixed, 95% CI)	1.55 [0.56, 4.33]
3 Number with adverse effects due to treatment	8	1199	Risk Ratio (M‐H, Random, 95% CI)	2.09 [0.83, 5.24]
4 Re‐operation	7	687	Risk Ratio (M‐H, Random, 95% CI)	1.26 [0.58, 2.70]
5 Anastomotic leak	9	1585	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.51, 1.27]
6 Pancreatic fistula (all)	17	2206	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.55, 0.79]
7 Pancreatic fistula (clinically significant)	4	292	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.38, 1.28]
8 Postoperative pancreatitis	11	1667	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.32, 1.22]
9 Sepsis	7	1092	Risk Ratio (M‐H, Fixed, 95% CI)	0.42 [0.21, 0.85]
10 Renal failure	5	998	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.25, 1.77]
11 Bleeding	14	1814	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.70, 1.44]
12 Abdominal collections	8	1589	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.56, 1.05]
13 Infected abdominal collections	13	1965	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.66, 1.32]
14 Delayed gastric emptying	5	434	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.51, 1.23]
15 Pulmonary complications	9	1210	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.57, 1.39]
16 Shock	4	812	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.46, 2.15]
17 Number of complications	7		Rate Ratio (Fixed, 95% CI)	0.70 [0.60, 0.82]
18 Number with any complication	12	1903	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.61, 0.80]
19 Hospital stay	10	1314	Mean Difference (IV, Fixed, 95% CI)	‐1.29 [‐2.60, 0.03]